MX2015010892A - Compuestos antivirales. - Google Patents

Compuestos antivirales.

Info

Publication number
MX2015010892A
MX2015010892A MX2015010892A MX2015010892A MX2015010892A MX 2015010892 A MX2015010892 A MX 2015010892A MX 2015010892 A MX2015010892 A MX 2015010892A MX 2015010892 A MX2015010892 A MX 2015010892A MX 2015010892 A MX2015010892 A MX 2015010892A
Authority
MX
Mexico
Prior art keywords
compounds
antiviral compounds
formula
variables
prevention
Prior art date
Application number
MX2015010892A
Other languages
English (en)
Inventor
Qingjie Ding
Nan Jiang
Robert J Weikert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015010892A publication Critical patent/MX2015010892A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención describe los compuestos de la Fórmula I: (ver Fórmula) en donde las variables en la Fórmula I se definen como se describe en la presente. También se describen composiciones farmacéuticas que contienen tales compuestos y métodos para utilizar los compuestos de la Fórmula I en la prevención o el tratamiento de la infección por VHC.
MX2015010892A 2013-03-05 2014-03-03 Compuestos antivirales. MX2015010892A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772936P 2013-03-05 2013-03-05
PCT/EP2014/054016 WO2014135472A1 (en) 2013-03-05 2014-03-03 Antiviral compounds

Publications (1)

Publication Number Publication Date
MX2015010892A true MX2015010892A (es) 2015-12-03

Family

ID=50190454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010892A MX2015010892A (es) 2013-03-05 2014-03-03 Compuestos antivirales.

Country Status (10)

Country Link
US (1) US20160002180A1 (es)
EP (1) EP2964626A1 (es)
JP (1) JP2016510050A (es)
KR (1) KR20150123917A (es)
CN (1) CN105051026A (es)
BR (1) BR112015021001A2 (es)
CA (1) CA2900826A1 (es)
MX (1) MX2015010892A (es)
RU (1) RU2015136816A (es)
WO (1) WO2014135472A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210261512A1 (en) * 2018-05-04 2021-08-26 Inflazome Limited Novel compounds
CN111518042B (zh) * 2020-05-29 2021-07-30 赣南师范大学 一种1,2,4-***类化合物及其制备方法
CN115047117B (zh) * 2022-07-18 2023-06-16 北京云鹏鹏程医药科技有限公司 一种同时测定利奈唑胺中3种遗传毒杂质的检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10123586A1 (de) * 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
ES2283851T3 (es) * 2002-08-13 2007-11-01 Warner-Lambert Company Llc Derivados de pirimidin-2,4-diona como inhibidores de las metaloproteinasas de matriz.
US20090018150A1 (en) * 2003-07-24 2009-01-15 Asterand Uk Limited 5-Ht2b Receptor Antagonists
US8492415B2 (en) * 2007-07-03 2013-07-23 Yale University Azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy (HIV)
AU2012363873B2 (en) * 2012-01-06 2017-11-23 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
MX2015011126A (es) * 2013-03-05 2015-11-11 Hoffmann La Roche Compuestos antivirales.

Also Published As

Publication number Publication date
JP2016510050A (ja) 2016-04-04
US20160002180A1 (en) 2016-01-07
EP2964626A1 (en) 2016-01-13
WO2014135472A1 (en) 2014-09-12
RU2015136816A (ru) 2017-04-07
CA2900826A1 (en) 2014-09-12
CN105051026A (zh) 2015-11-11
BR112015021001A2 (pt) 2017-07-18
KR20150123917A (ko) 2015-11-04

Similar Documents

Publication Publication Date Title
MX2015011193A (es) Compuestos antivirales.
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
PH12016501379A1 (en) Azepane derivatives and methods of treating hepatitis b infections
MY177804A (en) Hcv polymerase inhibitors
PH12017502363A1 (en) Brk inhibitory compound
NZ733174A (en) Quinazoline derivatives used to treat hiv
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
IN2015DN01156A (es)
EA201690979A1 (ru) Производные азепана и способы лечения инфекций гепатита в
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
MX2014015884A (es) Compuestos antivirales.
NZ703064A (en) Inhibitors of hepatitis c virus
PH12015502588B1 (en) 4`-fluoro-2`-methyl substituted nucleoside derivatives
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX2015011198A (es) Compuestos antivirales.
IN2014CN00572A (es)
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
PH12016500320A1 (en) Cyclosporin analogues for preventing or treating hepatitis c
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
MX2015009176A (es) Derivados de triazola antivirales.
MX2015010892A (es) Compuestos antivirales.
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
MX2015010790A (es) Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc.